The shares of Travelzoo (NASDAQ:TZOO) has been pegged with a rating of Speculative Buy by WBB Securities in its latest research note that was published on February 17, 2016. The Technology company has also assigned a $11 price target. WBB Securities wasn’t the only research firm that published a report of Travelzoo, with other equities research analysts also giving their opinion on the stock. The Benchmark Company advised investors in its research note published on February 12, 2016, to Hold the TZOO stock while also putting a $8 price target. The stock had earned Hold rating from The Benchmark Company Markets when it published its report on July 17, 2015. That day the The Benchmark Company set price target on the stock to $11. The stock was given Hold rating by The Benchmark Company in its report released on October 18, 2013, the day when the price target on the stock was placed at 25. Ascendiant Capital Markets was of a view that TZOO is Neutral in its latest report on July 19, 2013. Ascendiant Capital Markets thinks that TZOO is worth Neutral rating. This was contained in the firm’s report on May 21, 2013 in which the stock’s price target was also moved to 32.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $10.00. The price of the stock the last time has raised by 29.93% from its 52-Week high price while it is -82.71% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 31.02.
The shares of the company added by 12.86% during the trading session on Wednesday, reaching a low of $3.50 while ending the day at $3.95. During the trading session, a total of 517093.0 shares were traded which represents a -538.62% decline from the average session volume which is 80970.0 shares. TZOO had ended its last session trading at $3.50. Travelzoo currently has a market cap of $40.57 million, while its P/E ratio stands at 11.83, while its P/E earnings growth sits at 0.60, with a beta of 1.68. Travelzoo debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 0.90 TZOO 52-week low price stands at $3.04 while its 52-week high price is $22.85.
The Travelzoo generated 19.5 million in revenue during the last quarter. In the second quarter last year, the firm recorded $0.13 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 77.78%.
Investment analysts at Argus published a research note on March 24, 2020 where it informed investors and clients that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is now rated as Hold. Even though the stock has been trading at $74.18/share, analysts expect it to down by -5.76% to reach $186.00/share. It started the day trading at $77.05 and traded between $68.67 and $69.91 throughout the trading session.
A look at its technical shows that LGND’s 50-day SMA is 91.34 while its 200-day SMA stands at 101.04. The stock has a high of $130.50 for the year while the low is $57.24. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 7.9 M shorted shares, the short percentage went higher by 12.63%, as 8.90M TZOO shares were shorted. At the moment, only 50.28% of Ligand Pharmaceuticals Incorporated shares were sold short. The company’s P/E ratio currently sits at 2.38, while the P/B ratio is 1.57. The company’s average trading volume currently stands at 485.15K shares, which means that the short-interest ratio is just 16.30 days. Over the past seven days, the company moved, with its shift of -7.27%. Looking further, the stock has dropped -33.95% over the past 90 days while it lost -30.08% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The BlackRock Fund Advisors sold more LGND shares, decreasing its portfolio by -4.77% during the last quarter. This move now sees The BlackRock Fund Advisors selling -106,534 shares in the last quarter, thus it now holds 2,127,745 shares of LGND, with a total valuation of $199,156,932. Janus Capital Management LLC meanwhile bought more LGND shares in the recently filed quarter, changing its stake to $170,115,566 worth of shares.
Similarly, The Vanguard Group, Inc. decreased its Ligand Pharmaceuticals Incorporated shares by 4.34% during the recently filed quarter. After selling 1,549,770 shares in the last quarter, the firm now controls -70,346 shares of Ligand Pharmaceuticals Incorporated which are valued at $145,058,472. In the same vein, William Blair Investment Manageme… decreased its Ligand Pharmaceuticals Incorporated shares by during the most recent reported quarter. The firm bought 80,973 shares during the quarter which decreased its stakes to 1,445,675 shares and is now valued at $135,315,180. Following these latest developments, around 2.70% of Ligand Pharmaceuticals Incorporated stocks are owned by institutional investors and hedge funds.